Guardant Health Inc., a precision oncology company, has announced the results from the LIBERATE study, which have been published in ESMO Open. The study highlights the performance of Guardant Reveal, a blood test for detecting minimal residual disease $(MRD.AU)$ in patients with early-stage breast cancer. The results demonstrate the clinical validity and high performance of Guardant Reveal in predicting recurrence without the need for a tissue sample. The study retrospectively analyzed 290 blood samples from 95 patients, finding that Guardant Reveal demonstrated 100% sensitivity for distant recurrence in patients with ER+/HER2- breast cancer and 71% overall. Additionally, the test showed 100% specificity and a 100% positive predictive value for relapse. The findings indicate that post-operative detection of circulating tumor DNA (ctDNA) was significantly prognostic for event-free survival, with a median lead time of 152 days ahead of clinical recurrence. The full manuscript detailing these findings is available in ESMO Open.